stockrow
Friday 6 November 2026
Export XWEL’s income statement to Excel — free account
XWELL, Inc.
XWEL Healthcare Diagnostics & Research
XWELL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.2 million, down 13.8% from fiscal 2024.
- Revenue
- −7.08%
- EPS
- +53.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
0.56
0.01
−1.75%
Follow XWEL
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.31 | 0.30 | 0.09 | 0.19 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.95) | (1.85) | (60.90) | (2.71) | |
P/B ratio |
1.07 | 0.84 | 0.00 | 1.86 | |
Price to Tangible BV |
1.07 | 0.85 | 0.00 | 6.46 | |
EV/Sales |
0.08 | (0.11) | 0.18 | 0.19 | |
EV/EBITDA |
0.00 | 0.21 | 0.00 | 0.00 | |
EV/Operating CF |
(0.20) | 0.34 | (0.59) | (0.45) | |
EV/FCF |
(0.17) | 0.25 | (0.44) | (0.36) | |
Quick Ratio |
2.04 | 2.16 | 0.32 | 0.57 | |
Current Ratio |
2.27 | 2.35 | 0.46 | 1.08 | |
Net Debt/EBITDA |
6.31 | 3.26 | (0.15) | 13.12 | |
Debt/Assets |
0.00% | 0.00% | 32.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | (0.28) | 0.00 | |
Asset Turnover |
1.32 | 1.16 | 1.60 | 1.06 | |
Operating CF/Net income |
2.02 | 0.41 | 0.00 | 1.43 | |
Capex/Depreciation |
(0.72) | (1.52) | (0.28) | (2.11) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
65.08% | 114.42% | 81.85% | 21.16% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.10 | |
Share Based Compensation of Revenue |
1.37% | 13.35% | 2.28% | 3.23% | |
Graham Net Nets |
0.32 | 0.57 | (7.08) | (1.38) | |
Graham Number |
0.00 | 0.00 | 16.27 | 0.00 | |
Earnings Yield |
(511.54%) | (488.70%) | (1,110.87%) | (340.40%) | |
Free Cash Flow Yield |
(152.68%) | (141.87%) | (456.56%) | (265.12%) | |
Revenue per Share |
0.84 | 0.90 | 1.29 | 1.27 | |
Operating CF per Share |
(0.53) | (0.62) | (0.01) | (0.37) | |
Capex per Share |
(0.02) | (0.05) | (0.13) | (0.16) | |
Free Cash Flow per Share |
(0.55) | (0.67) | (0.13) | (0.53) | |
Cash per Share |
1.39 | 2.27 | 0.47 | 0.73 | |
Shareholders Equity per Share |
0.97 | 1.36 | (2.30) | 0.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 1.36 | (2.30) | 0.53 | |
Free Cash Flow |
(4.68) | (4.99) | (0.75) | (3.05) | |
Working Capital |
8.47 | 11.36 | (6.98) | 0.76 | |
Capital Expenditures |
(0.17) | (0.39) | (0.71) | (0.94) | |
Net Current Asset Value |
2.87 | 4.83 | (18.11) | (7.86) | |
EV/EBIT |
0.00 | 0.17 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.06 | 0.10 | 0.13 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.65 | 1.41 | 1.68 | 1.20 | |
Average Payables |
1.74 | 2.87 | 2.22 | 2.92 | |
Average Inventory |
0.48 | 0.49 | 0.51 | 0.59 | |
Average Assets |
21.49 | 24.91 | 18.28 | 27.76 | |
Average Common Equity |
5.98 | 6.47 | (2.53) | 8.95 |
Columns are period end dates · fundamentals updated 25 Oct 2026